A087010 Stock Overview
Peptron, Inc. engages in the development of peptide-based medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Peptron, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩26,800.00 |
| 52 Week High | ₩47,150.00 |
| 52 Week Low | ₩7,150.00 |
| Beta | 0.91 |
| 1 Month Change | 12.37% |
| 3 Month Change | -7.59% |
| 1 Year Change | 257.81% |
| 3 Year Change | 79.87% |
| 5 Year Change | 24.94% |
| Change since IPO | 28.85% |
Recent News & Updates
Does Peptron (KOSDAQ:087010) Have A Healthy Balance Sheet?
Feb 26
Peptron's (KOSDAQ:087010) Stock Price Has Reduced 53% In The Past Five Years
Dec 25Shareholder Returns
| A087010 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 6.3% | -3.7% | -4.3% |
| 1Y | 257.8% | -1.3% | -1.0% |
Return vs Industry: A087010 exceeded the KR Life Sciences industry which returned -1.3% over the past year.
Return vs Market: A087010 exceeded the KR Market which returned -1% over the past year.
Price Volatility
| A087010 volatility | |
|---|---|
| A087010 Average Weekly Movement | 12.9% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A087010's share price has been volatile over the past 3 months.
Volatility Over Time: A087010's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Ho-Il Choi | www.peptron.co.kr |
Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence.
Peptron, Inc. Fundamentals Summary
| A087010 fundamental statistics | |
|---|---|
| Market cap | ₩552.80b |
| Earnings (TTM) | -₩15.92b |
| Revenue (TTM) | ₩3.34b |
165.4x
P/S Ratio-34.7x
P/E RatioIs A087010 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A087010 income statement (TTM) | |
|---|---|
| Revenue | ₩3.34b |
| Cost of Revenue | ₩2.29b |
| Gross Profit | ₩1.05b |
| Other Expenses | ₩16.98b |
| Earnings | -₩15.92b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -771.90 |
| Gross Margin | 31.53% |
| Net Profit Margin | -476.43% |
| Debt/Equity Ratio | 25.0% |
How did A087010 perform over the long term?
See historical performance and comparison